Argenx
ARGX
HK$4,655
Share price
-1.03%
Change (1 day)
57.86%
Change (1 year)
Categories
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.
Revenue for Argenx (ARGX)
Revenue in 2024 (TTM): HK$17.05 Billion
According to Argenx
's latest financial reports the company's current revenue (TTM 
) is HK$16.98 Billion. an increase over the revenue in the year 2023 that were of HK$9.57 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Argenx from 2013 to 2024
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2024 | HK$17.00 B | 77.54% |
| 2023 | HK$9.57 B | 198.44% |
| 2022 | HK$3.20 B | |
| 2019 | HK$0.68 B | 199.21% |
| 2018 | HK$0.22 B | -41.9% |
| 2017 | HK$0.39 B | 196.14% |
| 2016 | HK$0.13 B | 105.79% |
| 2015 | HK$64.42 M | 43.67% |
| 2014 | HK$44.84 M | 16.72% |
| 2013 | HK$38.42 M |